|
|
||||||||
a Centre de Recherches du Service de Santé des Armées, La Tronche, France;
b Unité de Thérapie cellulaire, Service d'Hématologie Clinique, Groupe Hospitalier Pitié Salpétrière, Paris, France
Key Words. CD34+ cells • Bone marrow aplasia • Cell cycle • Nonhuman primate • Cytokines • Ex vivo expansion
M. Drouet, M.D., Ph.D., Experimental Radiohematology Unit, Centre de Recherches du Service de Santé des Armées, 24 avenue des Maquis du Grésivaudan BP 87-38702 La Tronche Cedex, France; Telephone 33-4-76-63-69-28.
Ex vivo expansion is a new strategy for hematopoietic stem and progenitor cell transplantation based on cytokine-induced amplification to produce grafts of controlled maturity. If the cell cycle position of CD34+ cells has been reported to govern their engraftment potential, the respective role of stem and progenitor cells in short- and long-term hematopoietic recovery remains debated. Studies focused on long-term engraftment potential suggest impairment when using cultured grafts, but the capacity to sustain short-term recovery is still controverted. The aim of this study was: A) to evaluate the consequences of cell cycle activation on short and long-term engraftment capacity, and B) to determine if cell cycle status of grafts could predict hematopoietic recovery. We showed in a nonhuman primate model of autologous peripheral blood stem and progenitor cell transplantation that cell cycle activation of CD34+ cells in the presence of stem cell factor + FLT3-ligand + thrombopoietin + interleukin 3 (six days of culture) which induced G1 and S/G2/M cell amplification (G0: 6.1% ± 2.8%; G0/G1: 64.2% ± 7.2%; S/G2/M: 30.4% ± 7.3% respectively of expanded CD34+ cells on average) resulted in the acceleration of short-term granulocyte recovery. By contrast, G0/G1 and S/G2/M cell content of expanded grafts did not correlate with short- or long-term engraftment.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
